Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with chemoradiotherapy vs chemotherapy in oligometastatic esophageal squamous cell carcinoma
ChiCTR2300070300Phase 3Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital & Institute
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sichuan Cancer Hospital & Institute. Primary endpoint: Median progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300070300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070300.